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As mentioned by the editors, the expectant readers of
Thrombosis in Clinical Practice are physicians, general
practitioners, nurse practitioners, and healthcare workers.
With this in mind I browsed Thrombosis in Clinical Prac-
tice.
Thrombosis is a fast moving area and is not easy to give
updated information of its pathophysiology and treat-
ment in about 300 pages as it was successfully done in this
book.
This multiauthored text combines basic concepts of mech-
anisms of thrombosis formation as well as therapeutic
approaches.
It provides short overviews on risk factors, therapeutics
and a systematic discussion of arterial and venous throm-
bosis management with final recommendations accord-
ing to the authors experience. It successfully delivers
concise information on all aspects of a given type of
thrombosis for physicians and nurses who care for
patients with thrombosis related diseases.
The first five chapters review the mechanism of thrombus
formation (although importance of inflammation was
omitted in Chapter 1), the role of the hemostatic system
in arterial and venous thrombosis, characteristics of what
the authors call "commonly used anticoagulant and
antiplatelet drugs" (which include aspirin, heparin, and
warfarin starting with an interesting historical perspective
of each of them).
Without doubt the risk of bleeding is the most critical
aspect of patients under antithrombotic treatment; "why
it happens and what to do" are questions answered in
Chapter 4.
Factors which determine thrombophilia are discussed in
Chapter 5. Practical recommendations for screening
patients with potential or already developed thrombotic
process are noteworthy.
The following Chapters 6 to 12 deal with treatment of
arterial and venous thrombosis and include management
of atrial fibrillation where the known, well established
therapies are discussed. In cardiac valves, Chapter 7, a
comprehensive indication for the used of oral anticoagu-
lant with or without aspirin and the management of preg-
nant patients was explained. Since some not so recent data
have been included in the beginning of this chapter
authors missed to mention that in patients with cardiac
valves prostheses, the first combined therapy (oral antico-
agulant plus dipyridamole) for thrombotic preventing
treatment was published by Sullivan et al. (N Engl J Med.
1971;284:1391-4), and belongs to our group the first
report on the use of aspirin plus oral anticoagulant (Alt-
man et al. J.Thorac.Cardiov. Surg. 72: 127,1976).
Chapters 8 to 11 review the benefit and risk of antithrom-
botic therapy in coronary artery disease, thrombosis pre-
vention after coronary interventions and, an updated
discussion on risk factors, pathophysiology, diagnosis
and antithrombotic therapy in peripheral arterial disease
and ischemic stroke.
Chapter 12 deals with an important and still controversial
topic: "Management of venous thromboembolism during
pregnancy". The authors discuss the conflictive positions
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in the diagnostic as well as in the treatment of deep
venous thrombosis in pregnant women. The antithrom-
botic treatment in women with recurrent miscarriage and
thrombophilia which is conflictive and still unresolved is
not discussed in this chapter.
Chapter 13 was dedicated to thrombophilia. I wonder
why it was included at the end of the book and not among
the first 5 Chapters. I also wonder why Ian Jennings omits
to discuss whether the decrease of fibrinolysis is (or not)
a potential thrombotic risk factor.
Importantly, a chapter on thrombosis in children was
incorporated in this book and finally, a chapter on new
drugs for anticoagulant therapy, which could be called
"the after coumadin/heparin era", was also included with
updated information on the pentasacharides fonda-
parinux and idraparinux, on drugs affecting factor VII
activity, direct Factor Xa and direct thrombin inhibitors.
Therapeutic characteristics of antiplatelet drugs is provide
in this Chapter. This part of the article shows the feeble
beneficial effect of clopidogrel plus aspirin, in reducing
the combining risk of ischemic stroke, MI or vascular
death compared with aspirin in several artery diseases and
likely to be beneficial in patients underwent percutaneous
coronary intervention. The antithrombotic capacity of
glicoprotein IIb-IIIa (integrin α2b/β3) inhibitors, the
potential value of von Willebrand factor antibody AJW
200 and thrombolytic therapy are also discussed.
This textbook is particularly interesting for general practi-
tioners, medical students and trainees in haematology. It
will be useful for physicians in several disciplines.
In short: It fulfils its stated purpose.Page 2 of 2
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